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ABSTRACT
Objectives: Chlamydial infection is often asymptomatic. The lack of symptoms may result in the infection developing 
into a chronic. Chlamydial infections of the genitourinary system in women can lead to serious complications like PID, 
fallopian tubes infertility, ectopic pregnancy, and chronic pelvic pain. An infection of the genitourinary system does not 
cause any lasting immune resistance and does not protect against re-infection. The aim of this research was to conduct 
tests for Chlamydia trachomatis on healthy women without any genital system symptoms and to estimate the frequency 
of asymptomatic infections.
Material and methods: During preventive examinations a cervical smear was obtained from the patients n = 100. The aver-
age age of the patients was 24.86 ± 3.15. The swabs were sampled by gynecologists. During the examinations Geneproof 
PathogenFree DNA isolation Kit and GeneProof Chlamydia trachomatis PCR kit which detects 16S rRNA conservative coding 
sequence, conservative region of cryptic plasmid DNA, including deletion mutation in cryptic plasmid (Swedish variant).
Results: Swabs were sampled from 100 women aged 18–32 who had no symptoms of chlamydial genitourinary system 
infection. Within the study group 4% of women received a positive result, i.e. 4/100.
Conclusions: The study confirmed asymptotic infection in 4% of women. In own research it was not possible to confirm cor-
relation between the presence of Chlamydia trachomatis and the number of partners or the number of sexual intercourses. 
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INTRODUCTION
Sexually transmitted infections are a serious issue among 
women. Chlamydia trachomatis is the most commonly spre-
ad STI (Sexually Transmitted Infection) pathogen [1].
In women, Chlamydia trachomatis causes inflammation 
of the urethra, cervix, fallopian tubes and pelvic organs. Cli-
nical symptoms in women are: mucopurulent inflammation 
of the cervix, with contact bleeding or without it, cervical 
tenderness, oedematous cervix, cervical ulcers, inflamma-
tion of the urethra, dysuria, vaginal discharge, postcoital ble-
eding and breakthrough bleeding, difficult to differentiate 
abdominal pain or lower abdomen pain [2, 3].
Chlamydial infection is often asymptomatic, so a person 
with proctitis or a genital infection may not be aware of its 
occurrence. The lack of symptoms may result in the infection 
developing into a chronic condition. Chlamydial infections 
of the genitourinary system in women can lead to serious 
complications like pelvic inflammatory disease (PID), which 
can be a factor causing fallopian tubes infertility, ectopic 
pregnancy, and chronic pelvic pain [1]. An infection of the 
genitourinary system does not cause any lasting immune 
resistance and does not protect against re-infection with 
Chlamydia trachomatis. In Europe, the Chlamydia tracho-
matis infection among people aged 18–26 is detected in 
3–5.3% of women and 2.4–7.3% of men, and 70–95% of the 
infections are asymptomatic [4].
Chlamydia trachomatis  is usually transmitted through di-
rect contact of a (vaginal, anal) mucous membrane during 
a sexual intercourse or oral sex or immediately after giving 
birth through the infected cervical canal of the mother. It is 
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estimated that the likelihood of transmission is around 10% 
during a single vaginal intercourse and around 55% with the 
patients who have had at least two sexual partners within six 
months. It is highly likely that partners of people infected with 
Chlamydia trachomatis  have also been infected, which is why it 
is so important to notify them and, subsequently, treat them [4].
Despite some literature reports on spontaneous regres-
sions of chlamydial infections, it is advised to carry out 
proper examinations in symptomatic and asymptomatic 
sexually active people, and, after identifying this pathogen, 
treating infected people along with the partners with whom 
they have been involved in the last 6 months [5, 6].
An indication for performing tests and a risk factor for 
an infection with Chlamydia trachomatis  or other STIs is 
age 25 or less, new sexual contact in the past year, more 
than one partner within 24 months, inflammation of the 
cervix or vaginal discharge in women with risk factors for 
STIs, acute pelvic pain and/or symptoms of PID, proctocolitis 
depending on the risk of STIs, diagnosing other STIs; ma-
intaining sexual intercourse with people with STIs or PIDs, 
terminating pregnancy, and any intrauterine interventions 
or manipulations [2].
The recommended diagnostic methods are nucle-
ic acid amplification tests (NAATs) that identify Chlamydia 
trachomatis’ DNA or RNA in clinical specimens because of 
their high sensitivity, specificity, and velocity. When genetic 
methods of detecting Chlamydia trachomatis  are not availa-
ble, direct fluorescent antibody (DFA) or insulation of Chlamy-
dia trachomatis  in cell culture can be used for diagnosis [7, 8].
Treating non complicated infections of the urogenital 
Chlamydia trachomatis  is based on oral administration of 
doxycycline at a dosage of 100 mg twice a day for 7 days 
(pregnancy is a contradiction) or a single administration of 
1 g azithromycin. Alternatively, erythromycin is administered 
orally at a dosage of 500 mg twice a day for 7 days, levofloxa-
cin orally at a dosage of 500 mg once a day for 7 days (pre-
gnancy is a contradiction), or ofloxacin at a dosage of 200 mg 
twice a day for 7 days (orally; pregnancy is a contradiction) [9].
It is also proposed to introduce multi-drug therapy, which 
seems to be more effective or natural products, the effecti-
veness of these methods has not yet been confirmed [10].
According to the recommendation, non-pregnant 
women ≤ 25 years old should be examined once a year 
(especially before the planned pregnancy), but pregnant 
women should be examined in the first and third trimester 
of pregnancy (recommended at the first visit). Non-pregnant 
women aged > 25 should be examined at least once a year, 
especially those taking risky sexual behavior (especially be-
fore the planned pregnancy), and pregnant women — test 
in the first trimester of pregnancy (recommended at the first 
visit), in the third trimester only in women at risk. It is also 
recommended to test the sexual partner once a year [11]. 
Unfortunately, the studies are not as applied and the positive 
results are not reported, which contributes in the spread of 
asymptomatic infections.
Aim of the study
The purpose of this research was to conduct tests for 
Chlamydia trachomatis  on healthy women without any 
genital system symptoms and to estimate the frequency 
of asymptomatic infections. 
MATERIAL AND METHODS
During preventive examinations a cervical smear was 
obtained from 100 patients. Swabs were sampled from 
100 women aged 18–32 who had no symptoms of chlamy-
dial genitourinary system infection. The average age of the 
patients was 24.86 ± 3.15. From the data collected from the 
patients, information about the number of partners within 
the last year before examination and the number of interco-
urses per week was obtained. Women declared an average 
of 1.14 partners within the last 24 months and 2.05 inter-
courses per week. The swabs were sampled by gynecologi-
sts. During the examinations Geneproof PathogenFree DNA 
isolation Kit and GeneProof Chlamydia trachomatis PCR kit 
which detects 16S rRNA conservative coding sequence, 
conservative region of cryptic plasmid DNA, including de-
letion mutation in cryptic plasmid (Swedish variant). The 
experimental protocol and informed consent procedure 
were in compliance with the Helsinki Convention and were 
approved by the ethics committee.
RESULTS
Within the study group 4% of women received a posi-
tive result, i.e. 4/100. All detected infections with Chlamy-
dia trachomatis were asymptotic. On the basis of Pearson 
correlation coefficient, there was no positive correlation 
between the number of partners and the occurrence of the 
infection (r = –0.043), and, similarly, the number of sexual 
intercourses did not correlate with the positive result of the 
test for Chlamydia trachomatis (r = 0.008).
Methods of statistical analysis
Verification of significance of differences between gro-
ups PCR = 0 and PCR = 1 (women with negative and posi-
tive PCR) was carried out using the Statistica 12 package. 
The study of the significance of differences in the variables 
examined due to the quantitative nature of the variables 
was preceded by the verification of the normality of the va-
riable distribution by the Shapiro-Wilk normality test in the 
cross-sections studied (positive and negative PCR). This test 
showed, for a variable number of partners and number of 
contacts, at least one of the examined distributions deviates 
significantly from the normal one, hence the non-parametric 
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U Mann-Whitney test was used for comparisons of 2 sub-
groups. In turn, the age of two distributions (PCR = 0 and 
PCR = 1) did not differ from normal hence the significance 
of differences comparisons (subject assumption of homoge-
neity of variance) was used t-test for independent samples.
Descriptive statistics represented by positional measu-
res: average, median, standard deviation (SD), minimum 
and maximum (Tab. 1).
A significance level of 0.05 was assumed.
There was no statistically significant (p = 0.370) differen-
ce in age in the group PCR = 0 and PCR = 1. In the group with 
negative results, the average age is 24.8 and differs from the 
mean by SD ± 3.2 versus mean age 26.3 and SD ± 3.1 in the 
group with positive PCR (Tab. 2).
There was no statistically significant difference in the 
number of partners (p = 0.862) and the number of contacts 
(p = 0.288) by groups of women with negative PCR and posi-
tive PCR. In the group with negative PCR, half of the subjects 
had no more than 1 partner (median) and the other half had 
no less than 1 partner with the same median in the group 
with positive PCR. In the group with negative PCR, half of 
the respondents declared no more than 2.0 contacts (me-
dian) and the other half did not less than 2.0 contacts with 
a median equal to 1.5 in the group with positive PCR (Tab. 3).
DISCUSSION
Infection with Chlamydia trachomatis in women may not 
cause any clinical symptoms. The patients that submit to 
medical check or preventive examinations for this patho-
gen can detect and confirm a chlamydial infection. In own 
research, after conducting PCR tests, positive results were 
obtained in 4% of the patients. According to some literature 
reports, the rate of Chlamydia trachomatis infections among 
women in Europe remains at the level of 3–5.3%. It is confir-
med by the results obtained during our research. It is also 
estimated that 70–95% of the infected women do not feel any 
discomfort in the genital system, which aids the uncontrolled 
spread of this microorganism. Undiagnosed and untreated 
patients are a potential reservoir of this bacterium [4].
 From 2008 to 2013, Bianchi conducted tests using ne-
sted PCR which detects chlamydial cryptic plasmid in the 
cervical smear of women who did not report any clinical 
Table 1. Descriptive statistics of study group
Descriptive statistics PCR N significant Average Median Minimum Maksimum
Lower 
quartile
Upper 
quartile
SD 
(standard 
deviation)
Age 0 97 24.8 25.0 18.0 32.0 22.0 27.0 3.2
Number of sex partners 0 97 1.2 1.0 1.0 3.0 1.0 1.0 0.5
Number of sex contacts 0 97 2.6 2.0 0.0 8.0 2.0  3.0 1.5
Age 1 4 26.3 27.0 22.0 29.0 24.0 28.5 3.1
Number of sex partners 1 4 1.3 1.0 1.0 2.0 1.0 1.5 0.5
Number of sex contacts 1 4 1.8 1.5 0.0 4.0 0.5 3.0 1.7
Table 2. T-test for independent samples of PCR results
T-test for 
independent 
samples
Average Average t df p N significant
N 
significant
SD (standard 
deviation)
SD (standard 
deviation) quotient F p
PCR PCR = 0 PCR = 1 PCR = 0 PCR = 1 PCR = 0 PCR = 1 the variance
the 
variance
Age 24.8 26.3 –0.9 99 0.370 97 4 3.2 3.1 1.0 1.000
T — result of the test; df — degrees of freedom; quotient F — homogeneity test of variance; p variances — the significance level of the F test
Table 3. Test U Manna-Whitneya for PCR results
Test U Manna-Whitneya
Sum.rang
Group 1 
(PCR =  0)
Sum.rang
Group 2 
(PCR = 1)
Z p
N significant.
Group 1 
(PCR = 0)
N significant.
Group 2 
(PCR = 1)
Number of sex partners 4936.5 214.5 –0.2 0.862 97 4
Number of sex contacts 5008.5 142.5 1.1 0.288 97 4
Z — result of the test
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signs of infection. Author detected the presence of Chlamy-
dia trachomatis in 4.4% of the patients; he noted the highest 
rate of infections in women aged 20–21, i.e. 5.5%, and the 
lowest rate in the age group 22–23 (3.5%). The differences 
between the results obtained in respective age groups by 
subsequent birth cohorts over the period of the examina-
tions were not significant [12].
Infection with Chlamydia trachomatis detected in wo-
man before pregnancy or at its early stage allows to avo-
id complications associated with rupture of membranes, 
preterm birth, and infection of the newborn. In Germany, 
a research was conducted to analyze the results of the tests 
for Chlamydia trachomatis obtained over the period 2008–
–2014. Dudareva-Vizule et al. found that 3.9% of women 
are infected with this microorganism. The highest rate of 
positive results was obtained in the age groups 15–19 (5%) 
and 20–24 (4.9%). Most of the women who underwent the 
tests were pregnant (41.9%) and these were preventive 
examinations. In the age group < 25, 26.9% of women un-
derwent screening tests [13].
The frequency of detecting infections depends on the 
region of the world and applied diagnostic methods. Refe-
rence methods are PCR genetic tests and, in case of limited 
possibilities of their application, fluorescent immunoassay 
or ELISA tests are used.
Arsić et al. during research conducted in the Balkan co-
untries, received significantly higher percentage of positive 
results. Using the ELISA method, Chlamydia trachomatis was 
detected in 7.1% (i.e. 100/1400) women in one of the centres 
while in Skopje, where DFA (direct fluorescent antibody 
assay) method was used, chlamydia antigen was detected 
in 6.8% (120/718) patients [14].
In previous own research, testing cervical smears for 
Chlamydia trachomatis in the years 2012–2013, out of wo-
men aged 18–30, by means of the DIF (direct immunoflu-
orescence) method infection was detected in 4/109 patients, 
i.e. 3.7%. It is a really similar to the current results obtained 
using the PCR method [15]. 
One of the partner’s infection with Chlamydia leads to 
a high risk of transmitting that pathogen to the other person 
during sexual intercourse. It is advised to undergo a test 
and treat simultaneously all the partners maintaining direct 
contacts. Berntsson et al. tested 99 women whose partners 
received a positive result for Chlamydia trachomatis. Using 
genetic methods they received positive results in 53 out of 
99 women (53.5%); of the women infected with Chlamydia 
trachomatis half the women did not declare any clinical 
symptoms, but the other patients experienced dysuria and 
vaginal discharge [16].
According to PZH (Państwowy Zakład Higieny) in Poland 
in 2015, 364 cases of chlamydiosis (incidence rate 0.95 per 
100 thousand inhabitants) were reported. However, these 
data do not reflect the facts, because there is no report of 
all detected infections and the lack of mandatory screening 
patients below < 25 years of age [17].
Młynarczyk-Bonikowska et al. examined the coexistence 
of Neisseria gonorhoeae and Chlamydia trachomatis infec-
tions in patients reporting to the Department of Dermato-
logy and Venerology, Warsaw Medical University. Among 
the 60 women surveyed, including chlamydia infection was 
1 patient, and 1 found in co-infections with N. gonorrhoeae. 
Among all examined men and women who did not manifest 
on the urogenital tract (n = 79), Chlamydia trachomatis was 
detected in 4 individuals, ie 5.06% [18].
The number of infected women may depend on the 
environmental factors that affect the culture and sexual 
behavior.
Torrone et al. analyzed positive results for Chlamydia 
trachomatis in the USA between 2007 and 2012. Among 
sexually active females, prevalence of chlamydia decreased 
with age (p < 0.05). Prevalence among sexually active fema-
les aged 14–24 years (the population targeted for chlamydia 
screening) was 4.7% overall and varied by race/ethnicity 
(p < 0.05). Among sexually active females aged 14–24 years, 
approximately 1 in 7 non-Hispanic black females was infec-
ted with chlamydia (13.5%); 1in 22 Mexican-American fe-
males was infected (4.5%), and 1 in 55 non-Hispanic white 
females was infected (1.8%) [19].
Sacramento et al. conducted research on prevalence of 
cervical Chlamydia trachomatis infection in sexually active 
adolescents from Salvador, Brazil. The overall prevalence 
of cervical Chlamydia trachomatis infection was 31%. There 
were no significant differences in the age at first sexual 
intercourse and condom use between Chlamydia tracho-
matis infected and uninfected adolescents. About 10% of 
the infected women have had five or more sexual partners 
in their lifetime, while 5.8% of uninfected patients repor-
ted the same. However, this difference was not statistically 
significant [20]. 
Our study confirmed asymptotic infection in 4% of 
women. In own research it was not possible to confirm 
correlation between the presence of Chlamydia trachomatis 
and the number of partners or the number of sexual inter-
courses. This is due to the small number of patients and too 
low percentage of positive results. 
RESULTS
Continuation of the tests will undoubtedly allow to es-
timate and confirm the risk factors for the occurrence of 
Chlamydia trachomatis infection. Asymptomatic infections 
are not diagnosed and properly treated, what result further 
complications of chronic infections. Annual preventive exa-
minations of women and partners would reduce the number 
of newly infected people.
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